Literature DB >> 21718310

Consequences of splice variation on Secretin family G protein-coupled receptor function.

Sebastian G B Furness1, Denise Wootten, Arthur Christopoulos, Patrick M Sexton.   

Abstract

The Secretin family of GPCRs are endocrine peptide hormone receptors that share a common genomic organization and are the subject of a wide variety of alternative splicing. All GPCRs contain a central seven transmembrane domain responsible for transducing signals from the outside of the cell as well as extracellular amino and intracellular carboxyl termini. Members of the Secretin receptor family have a relatively large N-terminus and a variety of lines of evidence support a common mode of ligand binding and a common ligand binding fold. These receptors are best characterized as coupling to intracellular signalling pathways via G(αs) and G(αq) but are also reported to couple to a multitude of other signalling pathways. The intracellular loops are implicated in regulating the interaction between the receptor and heterotrimeric G protein complexes. Alternative splicing of exons encoding both the extracellular N-terminal domain as well as the extracellular loops of some family members has been reported and as expected these splice variants display altered ligand affinity as well as differential activation by endogenous ligands. Various forms of alternative splicing have also been reported to alter intracellular loops 1 and 3 as well as the C-terminus and as one might expect these display differences in signalling bias towards downstream effectors. These diverse pharmacologies require that the physiological role of these splice variants be addressed but should provide unique opportunities for drug design and development.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Mesh:

Substances:

Year:  2012        PMID: 21718310      PMCID: PMC3415641          DOI: 10.1111/j.1476-5381.2011.01571.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  75 in total

1.  Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1.

Authors:  Augen A Pioszak; Naomi R Parker; Kelly Suino-Powell; H Eric Xu
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

Review 2.  Emerging role of alternative splicing of CRF1 receptor in CRF signaling.

Authors:  Michał A Zmijewski; Andrzej T Slominski
Journal:  Acta Biochim Pol       Date:  2010-03-16       Impact factor: 2.149

3.  Modulation of corticotropin releasing factor (CRF) signaling through receptor splicing in mouse pituitary cell line AtT-20--emerging role of soluble isoforms.

Authors:  M A Zmijewski; A T Slominski
Journal:  J Physiol Pharmacol       Date:  2009-10       Impact factor: 3.011

4.  Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.

Authors:  Steffen Runge; Henning Thøgersen; Kjeld Madsen; Jesper Lau; Rainer Rudolph
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

5.  Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor.

Authors:  Kaleeckal G Harikumar; Renee M Happs; Laurence J Miller
Journal:  Biochim Biophys Acta       Date:  2008-07-17

6.  Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor.

Authors:  Fan Gao; Kaleeckal G Harikumar; Maoqing Dong; Polo C-H Lam; Patrick M Sexton; Arthur Christopoulos; Andrew Bordner; Ruben Abagyan; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2009-05-08       Impact factor: 4.436

7.  Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: lessons from the receptor variant R1d.

Authors:  Danijela Markovic; Hendrik Lehnert; Michael A Levine; Dimitris K Grammatopoulos
Journal:  Mol Endocrinol       Date:  2008-09-04

8.  Soluble corticotropin-releasing hormone receptor 2alpha splice variant is efficiently translated but not trafficked for secretion.

Authors:  Ryan T Evans; Audrey F Seasholtz
Journal:  Endocrinology       Date:  2009-06-11       Impact factor: 4.736

9.  CRF1 receptor splicing in epidermal keratinocytes: potential biological role and environmental regulations.

Authors:  Michal A Zmijewski; Andrzej T Slominski
Journal:  J Cell Physiol       Date:  2009-03       Impact factor: 6.384

10.  A general definition and nomenclature for alternative splicing events.

Authors:  Michael Sammeth; Sylvain Foissac; Roderic Guigó
Journal:  PLoS Comput Biol       Date:  2008-08-08       Impact factor: 4.475

View more
  19 in total

1.  Secretin family (Class B) G protein-coupled receptors - from molecular to clinical perspectives.

Authors:  David R Poyner; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

Authors:  C S Walker; T Sundrum; D L Hay
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 4.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 5.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Authors:  K Pabreja; M A Mohd; C Koole; D Wootten; S G B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 6.  Lighting up Nobel Prize-winning studies with protein intrinsic disorder.

Authors:  Lolita Piersimoni; Marina Abd El Malek; Twinkle Bhatia; Julian Bender; Christin Brankatschk; Jaime Calvo Sánchez; Guy W Dayhoff; Alessio Di Ianni; Jhonny Oscar Figueroa Parra; Dailen Garcia-Martinez; Julia Hesselbarth; Janett Köppen; Luca M Lauth; Laurin Lippik; Lisa Machner; Shubhra Sachan; Lisa Schmidt; Robin Selle; Ioannis Skalidis; Oleksandr Sorokin; Daniele Ubbiali; Bruno Voigt; Alice Wedler; Alan An Jung Wei; Peter Zorn; Alan Keith Dunker; Marcel Köhn; Andrea Sinz; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2022-07-26       Impact factor: 9.207

Review 7.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

8.  Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Δ(1-47)hCT((a)) function.

Authors:  T Qi; M Dong; H A Watkins; D Wootten; L J Miller; D L Hay
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

9.  Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin.

Authors:  Rebekah L Bower; Lauren Yule; Tayla A Rees; Giuseppe Deganutti; Erica R Hendrikse; Paul W R Harris; Renata Kowalczyk; Zachary Ridgway; Amy G Wong; Katarzyna Swierkula; Daniel P Raleigh; Augen A Pioszak; Margaret A Brimble; Christopher A Reynolds; Christopher S Walker; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2018-04-23

10.  Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity.

Authors:  Janna Blechman; Gil Levkowitz
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.